30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q13 Revenue: Zimmer

$1,139MM, +1% (Americas $635MM, flat; Europe $307MM, +2%; Asia Pacific $197MM, +3%)

Reconstructive $850MM, -1% (Americas $465MM, -1%; Europe $242MM, +1%; Asia Pacific $143MM, flat)

  • Hips $331MM, -2% (Americas $152MM, -1%; Europe $112MM, -2%; Asia Pacific $67MM, -5%)
  • Knees $471MM, flat (Americas $275MM, -2%; Europe $123MM, +3%; Asia Pacific $73MM, +4%)
  • Extremities $48MM, +7%

Dental $60MM, -1%

Trauma $82MM, +11%

Spine $47MM, -10%

Surgical/Other $100MM, +17%


  • Overall price pressure -2.0% (stable from prior year); hips reflect positive volume and mix of 0.5%, negative price -2.9%; knees reflect positive volume and mix of 2.2%, negative price of -2.2%
  • Received FDA 510(k) clearance of Avenir hip stem, compatible with anterior supine approach
  • Launched Persona Personalized Knee system, to excellent clinical feedback from 1st several thousand cases; launched iASSIST Personalized Guidance system
  • Introduced Trabecular Metal Total Ankle, with advanced bearing materials, anatomically-matched shapes/sizes, supports a lateral approach
  • Received FDA 510(k) clearance for Nexel next-generation elbow
  • Trauma growth supported by Natural Nail in all regions, increased plate/screw sales including NCB Periprosthetic Plate
  • Just beginning launch of Apex system for deformity/complex spinal cases
  • Expects resolution in 2H13 of issues related to PEEK Ardis Interbody Inserter voluntary recall
  • Recording meaningful contributions from Gel-One Hyaluronate